DRG Market Assessment reports

This three-wave syndicated research series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…

Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and…

The prevalence of the often disabling psychiatric diseases schizophrenia and major depressive disorder (MDD) is growing in Brazil and Mexico. Antipsychotics (older typical or newer atypical…

The positive symptoms of schizophrenia (e.g., hallucinations, delusions) are a symptom domain of schizophrenia that affects approximately 83% of the 3.2 million diagnosed prevalent cases of…

The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…

The U.S. therapy market for the SpA indications PsA, AS, and nr-AxSpA is becoming increasingly crowded as new biologics and SMIs offering novel MOAs enter the market and compete for preferential…

Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United…

Biomarker- and histology-driven prescribing has become standard practice in the treatment of non-small-cell lung cancer (NSCLC). The treatment algorithms for NSCLC—including those for biomarker-…

Abstract Introduction: With a growing number of biosimilars in development and the launch of the first FDA-approved products in 2015, biosimilars are set to gain an increasing share of the…

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the United States and Europe. The majority of patients with advanced AMD have the wet form of the…

Schizophrenia is a chronic and disabling psychiatric condition that affects approximately 1.8 million Americans. Patients with schizophrenia can present with a range of symptoms that are…

With no significant drug launches occurring in more than a decade, the overarching treatment paradigms in Alzheimer’s disease (AD) are mostly stable. However, understanding what factors and…